What is the main purpose of this 8-K filing?

This 8-K filing primarily announces the election of two new independent directors, James H. Hinton and Kathleen Wilson-Thompson, to McKesson Corporation's Board of Directors. It also provides details on their backgrounds, expected committee assignments, and compensation.

What kind of experience do the new directors bring to McKesson?

James H. Hinton brings significant experience in healthcare operations and leadership, having served as CEO of large healthcare systems. Kathleen Wilson-Thompson brings extensive expertise in human resources and executive leadership from her roles at major corporations like Walgreens Boots Alliance and Kellogg Company.

How will these new directors be compensated?

Mr. Hinton and Ms. Wilson-Thompson will receive the standard compensation package for non-employee directors, which includes an $80,000 annual cash retainer (prorated) and restricted stock units (RSUs) with an approximate initial value of $94,191.78 (also prorated). They will also enter into the company's standard director indemnification agreement.

Are there any financial implications directly tied to these director appointments?

The filing details the compensation structure for the new directors, which will result in additional compensation expenses. However, this filing does not report any new financial results or material financial events for the company itself.

MCK 8-K: Leadership Changes & Regulation FD

Summary

McKesson Corporation (MCK) announced on January 18, 2022, the election of two new independent directors to its Board of Directors: James H. Hinton and Kathleen Wilson-Thompson. These appointments, effective January 13, 2022, bring valuable experience in healthcare leadership and human resources, respectively, to McKesson's governance structure. Mr. Hinton, with a background as CEO of large healthcare systems, and Ms. Wilson-Thompson, a former executive at Walgreens Boots Alliance and Kellogg Company, are expected to enhance the Board's expertise in critical areas. The addition of these directors signals a commitment by McKesson to strengthen its Board's oversight and strategic guidance. Both new directors will participate in the standard compensation arrangements for non-employee directors, including an annual cash retainer and restricted stock units, as well as enter into the company's standard indemnification agreement. Their appointments are expected to bolster the Board's effectiveness and align with the company's ongoing strategic objectives.

Key Highlights

1McKesson appointed James H. Hinton and Kathleen Wilson-Thompson as new independent directors to its Board of Directors, effective January 13, 2022.
2James H. Hinton brings extensive experience from leadership roles at major healthcare organizations, including Baylor Scott & White Health and Presbyterian Healthcare Services.
3Kathleen Wilson-Thompson offers significant expertise in human resources and executive leadership from her tenure at Walgreens Boots Alliance and Kellogg Company.
4The new directors are expected to serve on key Board committees: Mr. Hinton on the Compliance and Governance Committees, and Ms. Wilson-Thompson on the Compensation and Governance Committees.
5Both directors will receive standard compensation for non-employee directors, including an $80,000 annual cash retainer (prorated) and restricted stock units (RSUs) valued at approximately $94,191.78 (prorated).
6The appointments are intended to enhance the Board's oversight and strategic direction for McKesson Corporation.
7The company issued a press release on January 18, 2022, to announce these director elections.

MCKESSON CORP 8-K Report, Executive Changes (Jan 18, 2022)

Summary

Key Highlights

Frequently Asked Questions